Tang-Du Hospital — CureCurrent

Published trials62

Recruiting shown15

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%NCT07596121 · lead sponsor · 2026-05-13

Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)NCT07354061 · lead sponsor · 2026-03-25

Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance TherapyNCT07141264 · lead sponsor · 2025-08-25

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLCNCT06864624 · lead sponsor · 2025-02-18

Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized TrialNCT06485544 · lead sponsor · 2024-07-01

Adebrelimab + Apatinib in SCLC Maintenance TherapyNCT06475209 · lead sponsor · 2024-06-20

Partial Pressure of Oxygen Control Method in Identification of Intersegmental PlaneNCT06644066 · lead sponsor · 2024-05-01

Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung CancerNCT06467786 · lead sponsor · 2024-03-15

Assessment of Brain Cognitive Impairment in Breast CancerNCT05305092 · lead sponsor · 2022-05-31

The Early Warning System for the Diabetic EncephalopathyNCT02420470 · lead sponsor · 2015-04-01

Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast CancerNCT07618923 · lead sponsor · 2026-06-01

NOT_YET_RECRUITING

Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung CancerNCT07538193 · lead sponsor · 2026-05-01

NOT_YET_RECRUITING

Anesthesia Comparison in Early-stage Small NSCLC: A Multicenter RCTNCT07327736 · lead sponsor · 2026-03-15

NOT_YET_RECRUITING

This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung CancerNCT06978153 · lead sponsor · 2025-05-20

NOT_YET_RECRUITING

This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete ResponseNCT06851169 · lead sponsor · 2025-04-01

NOT_YET_RECRUITING

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLCNCT06485557 · lead sponsor · 2024-08-01

A Study to Prospectively Validate Blood Markers Associated With Differences in Efficacy of Neoadjuvant Therapy for NSCLCNCT06503042 · lead sponsor · 2024-08-01

3D-Printed Artificial Airway Fixation Device for Obese PatientsNCT07349433 · lead sponsor · 2024-07-09

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLCNCT06475755 · lead sponsor · 2024-06-30

NOT_YET_RECRUITING

Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT ParameterNCT06441357 · lead sponsor · 2024-06-01

Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell CarcinomaNCT06436040 · lead sponsor · 2024-01-24

Bacteria in Atherosclerotic Plaques and Adverse EventsNCT06935279 · lead sponsor · 2024-01-01

Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE)NCT05430802 · lead sponsor · 2023-01-10

ACTIVE_NOT_RECRUITING

Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal HypertensionNCT06245798 · lead sponsor · 2023-01-01

Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung CancerNCT05387109 · lead sponsor · 2022-06-30

An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain MetastasisNCT06352502 · lead sponsor · 2022-01-28

Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLCNCT05167604 · lead sponsor · 2021-09-30

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLCNCT05055583 · lead sponsor · 2021-08-31

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLCNCT05400070 · lead sponsor · 2021-03-01

ACTIVE_NOT_RECRUITING

Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLCNCT04338620 · lead sponsor · 2020-04-07

A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLCNCT04840290 · lead sponsor · 2019-06-01

Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC PatientsNCT03613467 · lead sponsor · 2018-07-04

A Study to Explore Prognoses of NSCLC Patients Complicated With OligometastasesNCT03427541 · lead sponsor · 2017-12-31

A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase InhibitorsNCT03424980 · lead sponsor · 2017-12-31

A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung CancerNCT03451526 · lead sponsor · 2017-12-01

Chidamide in Combination With ART for Reactivation of the Latent HIV-1 ReservoirNCT02902185 · lead sponsor · 2016-11-29

Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 ReservoirNCT02513901 · lead sponsor · 2015-08-01

Role of Bronchoscopy in Early Lung Cancer Screening of High Risk PopulationNCT02277366 · lead sponsor · 2015-05-01

Diagnosis of Individuals With Pulmonary Nodules by Different Bronchoscopy CombinationNCT02268162 · lead sponsor · 2015-04-01

Multiple B-value Diffusion-weighted Imaging(DWI) in Evaluation of Breast LesionsNCT02529384 · lead sponsor · 2015-01-01

Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung AdenocarcinomaNCT02518802 · lead sponsor · 2015-01-01

Preventive Effects of Zoledronic Acid on Bone Metastasis in Patients With Stage IIIB and IV Lung CancerNCT02622607 · lead sponsor · 2013-01-01

Effect of a Pharmacist-led Multifaceted Intervention on Treatment Outcomes in Hypertensive PatientsNCT06558877 · collaborator · 2025-06-20

Clinical Efficacy and Safety Assessment of Breast-Conserving Surgery for Central Breast Cancer: A Prospective Randomized Controlled TrialNCT06938360 · collaborator · 2025-02-20

Advantage of Cerebellar Transcranial Magnetic Stimulation in Alzheimer's Diseases （ACT-AD）NCT06669182 · collaborator · 2025-01-07

The Chinese Familial Alzheimer's NetworkNCT03657732 · collaborator · 2005-01-10

China Cognition and Aging StudyNCT03653156 · collaborator · 2000-01-01

A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Taurine as an Adjunctive Therapy in Multiple SclerosisNCT07263607 · collaborator · 2026-01-01

NOT_YET_RECRUITING

Assessing the Effectiveness of Continuous Glucose Monitoring in Enhancing Surgical Outcomes for Patients With DiabetesNCT06331923 · collaborator · 2024-04-12

Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA SequencingNCT06036563 · collaborator · 2023-09-01

Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)NCT06577792 · collaborator · 2023-08-16

ACTIVE_NOT_RECRUITING

ENB Guided MWA Combined With VATS Versus Sequential Surgery for Synchronous Bilateral Multiple Primary Lung NodulesNCT05662553 · collaborator · 2023-02-01

Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass OpacitiesNCT04982900 · collaborator · 2021-10-01

Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)NCT06524427 · collaborator · 2020-08-25

ACTIVE_NOT_RECRUITING

SBRT With S1 Combined With Endostar in the Treatment of Lung CancerNCT04274270 · collaborator · 2020-04-01

Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLCNCT04182698 · collaborator · 2019-11-22

Controlling Hypertension After Severe Cerebrovascular EventNCT02982655 · collaborator · 2017-01-01

Multi-center Imaging Genetics Studies in ChinaNCT02681822 · collaborator · 2015-11-01

Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected AdultsNCT02231281 · collaborator · 2014-08-01

Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR MutationNCT01405079 · collaborator · 2011-09-19

Sponsor roles

lead sponsor42

collaborator20

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.